PDF
Word
This version of the form is not currently in use and is provided for reference only. Download this version of
Form HLTH5814
for the current year.
Form HLTH5814 Special Authority Request - Edaravone for Amyotrophic Lateral Sclerosis (Als) - British Columbia, Canada
Form HLTH5814 Special Authority Request - Edaravone for Amyotrophic Lateral Sclerosis (ALS) is specifically for requesting special authority to access the medication Edaravone for the treatment of ALS in British Columbia, Canada.
The form HLTH5814 Special Authority Request for Edaravone for Amyotrophic Lateral Sclerosis (ALS) in British Columbia, Canada is typically filled out by healthcare professionals or physicians on behalf of patients.
FAQ
Q: What is HLTH5814?
A: HLTH5814 is a form for a Special Authority Request in British Columbia, Canada.
Q: What is Edaravone?
A: Edaravone is a medication used for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Q: What is ALS?
A: ALS, or Amyotrophic Lateral Sclerosis, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
Q: What is a Special Authority Request?
A: A Special Authority Request is a process through which certain medications or treatments can be approved for coverage by the government health program.
Q: Who is eligible for a Special Authority Request?
A: Eligibility for a Special Authority Request may vary depending on the specific criteria set by the government health program.
Q: Why would someone need a Special Authority Request for Edaravone?
A: A Special Authority Request for Edaravone may be required to obtain coverage for the medication if it is not automatically covered under the government health program.
Q: Is the Special Authority Request specific to British Columbia, Canada?
A: Yes, the Special Authority Request is specific to the province of British Columbia in Canada.
Q: What are the next steps after submitting the Special Authority Request?
A: After submitting the Special Authority Request, the request will be reviewed by the government health program to determine if coverage for Edaravone will be approved.
Q: Is Edaravone the only treatment for ALS?
A: No, there are other treatments available for ALS. Edaravone is just one of the options.
Download Form HLTH5814 Special Authority Request - Edaravone for Amyotrophic Lateral Sclerosis (Als) - British Columbia, Canada
1
2
